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Background: The relationship between provider experience and 
clinical outcomes is poorly defined in radiation oncology. This study 
examined the impact of facility case volume on overall survival in 
patients with stage III non–small cell lung cancer (NSCLC) treated 
with definitive concurrent chemoradiation therapy (CCRT).
Methods: Using the National Cancer Data Base, we identified clini-
cal stage III NSCLC patients diagnosed in 2004 to 2006 who were 
treated with definitive CCRT to 59.4–74.0 Gy. High-volume facilities 
(HVF) were defined as those in the ninetieth percentile of annual 
CCRT volume (≥12 cases/year). Independent predictors of receiv-
ing CCRT at HVF were identified using multivariable logistic regres-
sion. Overall survival based on receiving CCRT at HVF was assessed 
using Kaplan–Meier analysis, Cox proportional hazards regression, 
and propensity score matching.
Results: Among 10,072 included patients, 1207 (12.0%) were treated 
at HVF. Patients in HVF were more likely to have a higher Charlson–
Deyo comorbidity score, more advanced nodal stage, higher doses, 
and 3D-conformal or intensity-modulated radiotherapy. When con-
trolling for demographic and clinical covariates including academic 
affiliation, treatment at HVF was independently associated with a 
significantly decreased risk of death (hazards ratio = 0.93; 95% con-
fidence interval: 0.87–0.99; p = 0.03). Propensity score matching 
showed that these findings were robust (hazards ratio = 0.91; 95% 
confidence interval: 0.84–0.99; p = 0.04).
Conclusions: Our findings suggest that treatment at HVF is associ-
ated with improved overall survival among stage III NSCLC patients 
receiving definitive CCRT, independent of academic affiliation. 
Further research is needed to determine whether or not efforts sup-
porting centralization of radiotherapy at HVF will improve popula-
tion-based survival, toxicities, and costs.
Key Words: Radiation therapy, facility volume, case volume, non–
small-cell lung cancer, survival.
(J Thorac Oncol. 2015;10: 937–943)
Lung cancer remains the leading cause of cancer mortal-ity in the United States, with approximately 224,000 
new diagnoses and 159,000 deaths estimated in 2014.1 
Approximately 87% of these patients have nonsmall-cell lung 
cancer (NSCLC), and survival for locoregionally advanced 
disease is approximately 26% at 5 years after diagnosis.2 For 
patients with locally advanced stage III NSCLC, National 
Comprehensive Cancer Network guidelines support the use 
of definitive concurrent chemoradiation therapy (CCRT) as 
a standard-of-care treatment option.3 Numerous studies have 
identified greater provider experience and higher hospital 
volume as predictors of improved outcomes, particularly for 
patients undergoing specialized oncologic surgeries, such as 
pancreaticoduodenectomy or lung lobectomy.4–18 However, 
few studies have investigated the association between case 
volume and patient outcomes for radiotherapy (RT), espe-
cially in lung cancer.19–22
RT treatment planning and delivery for NSCLC can 
be quite complex and variable given the myriad choices of 
radiation modalities, CCRT regimens, and protocols cur-
rently available.23–26 In addition, high-volume facilities (HVF) 
have been reported to have higher rates of protocol compli-
ance, a factor shown to correlate with improved outcomes.27,28 
CCRT for NSCLC is also frequently complicated by acute and 
chronic toxicities, often requiring a network of experienced 
diagnostic, therapeutic, and support services to ensure opti-
mal patient outcomes.29–31 Because of the increasingly com-
plex and multidisciplinary nature of locally advanced NSCLC 
treatment, we hypothesize that treatment at HVF with exper-
tise in treating a large number of CCRT cases may be associ-
ated with improved overall survival.
In the current study, we used data from the National 
Cancer Data Base (NCDB) for patients who were treated with 
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definitive CCRT for stage III NSCLC diagnosed and clini-
cally staged between 2004 and 2006. Our primary objective 
was to investigate the relationship between RT facility volume 
and overall survival. We also assessed potential associations 
between various demographic and clinicopathologic charac-
teristics and receipt of RT at HVF versus low-volume facilities 
(LVF). Finally, we sought to identify other factors associated 
with improved survival among patients with locally advanced 
NSCLC who received CCRT.
MATERIALS AND METHODS
National Cancer Data Base
We performed a retrospective analysis of United States 
national practice using the NCDB. The NCDB is a joint proj-
ect of the Commission on Cancer (CoC) of the American 
College of Surgeons and the American Cancer Society. It 
contains de-identified information from approximately 70% 
of newly diagnosed cancers in the United States. NCDB con-
tains information that is unavailable in the surveillance, epide-
miology, and end results database, including treatment details 
pertaining to RT dose, technique, and target. The data used 
in this study are derived from a de-identified NCDB file. The 
American College of Surgeons and the CoC have not veri-
fied and are neither responsible for the analytic or statistical 
methodology employed nor the conclusions drawn from these 
data by the investigators. The Yale Human Investigations 
Committee determined that this study was exempt from 
review given that it used existing and de-identified data.
Patient Identification
We identified patients 18 years of age or older treated 
with definitive CCRT with clinical stage III NSCLC (cT1-4/
cN2-3/cM0, cT3-4/cN1/cM0, or cT4/cN0/cM0, based on 
American Joint Committee on Cancer 6th edition classifica-
tion) who were diagnosed and clinically staged in 2004 to 2006. 
Included International Classification of Diseases-O-3 histol-
ogy codes are listed in Supplemental Table 1 (Supplemental 
Digital Content, http://links.lww.com/JTO/A819). CCRT was 
defined as (1) starting RT within 30 days of chemotherapy 
initiation or (2) starting chemotherapy before the end of the 
RT course. We excluded patients with unknown vital status 
or follow-up information and those with missing information 
on facility type. In addition, patients who underwent surgical 
resection as part of the first planned course of treatment, who 
had unknown or missing treatment data, or did not receive 
RT at the reporting facility were excluded (Fig. 1). We fur-
ther restricted our study population to patients who received a 
total RT dose within the range of 59.4 to 74.0 Gy in 30 to 37 
fractions to reduce the potential for misclassification due to 
miscoding during data submission to NCDB.
Statistical Methods
To estimate RT facility volume, we assigned an aver-
age annual volume to each facility appearing in the NCDB. 
This was achieved by dividing the total number of CCRT 
cases reported by each facility by the number of years of 
accreditation between 2004 and 2006. Because the number of 
CoC-accredited cancer programs changes from one diagnosis 
year to the next, not all of the hospitals available in the NCDB 
were accredited for every one of the diagnosis years included 
over the study period. HVF were defined before analysis as 
those belonging in the ninetieth percentile of annual RT vol-
ume rounded to the nearest whole number, with the remainder 
aggregated as LVF.32,33 We also performed a sensitivity analy-
sis with alternative HVF definitions in an attempt to identify a 
threshold of facility case volume needed to achieve improved 
outcomes.
Demographic factors included in the analysis included 
age at diagnosis, race, 2000 census tract annual median 
income, insurance status, geographic region, patient location 
(rural, metro, and urban), travel distance to reporting facility, 
and Charlson/Deyo comorbidity score. Clinical characteris-
tics, defined at the patient level, included RT modality (three-
dimensional conformal RT, intensity-modulated RT, and 
nonconformal RT), total RT dose–fractionation, and year of 
diagnosis. Facility-level characteristics included hospital type 
and treatment volume. Classification of hospital academic sta-
tus was made based on the cancer program category assigned 
by the CoC for each facility. Academic Comprehensive Cancer 
Program facilities (postgraduate medical education in at least 
four areas and more than 500 newly diagnosed cancer cases 
per year) were classified as academic, whereas Comprehensive 
Community Cancer Program (>500 newly diagnosed cancer 
cases per year), Community Cancer Program (100–500 newly 
diagnosed cancer cases per year), and other facilities were 
classified as nonacademic.
The NCDB requires hospital registries to update vital 
status and other information in 5-year cycles. At the time of 
the current study, overall survival was available for patients 
diagnosed up to 2006. Patients entered the study on their date 
of diagnosis and were followed until the most recent date of 
last contact, death, or the end of the study period. Our primary 
FIGURE 1.  Exclusion criteria used to determine the final 
study cohort.
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outcome measure was overall survival because outcome data 
regarding locoregional control, distant control, and cancer-
specific survival are not available in NCDB.
The distribution of categorical demographic, clinical, 
and facility details was compared between patients treated 
in HVF versus LVF using Pearson’s χ2 test and Wilcoxon-
rank sum test, as appropriate. Multivariable logistic regres-
sion modeling was used to identify predictors of treatment at 
HVF versus LVF. Kaplan–Meier analysis was used to compare 
overall survival between patients receiving CCRT at HVF 
versus LVF. We used multivariable Cox regression modeling 
as the primary analytic strategy to determine the association 
between overall survival and facility volume after adjusting 
for all significant covariates.
Sensitivity analysis was performed using propensity-
score matched pairs as an alternative method of comparison 
in the primary cohort. Propensity matching is a technique 
in which quasicase/control pairs are produced from a retro-
spective cohort to simulate randomized controlled trials that 
attempt to balance measured and unmeasured confounders.34 
For our cohorts, patients who received treatment in HVF were 
matched to patients treated at LVF who have a similar propen-
sity of being treated in either facility type. Matching was per-
formed after randomly ordering patients using the psmatch2 
algorithm35 in Stata SE version 13.0, with one to one nearest-
neighbor matching without replacement.36 Standard summary 
statistics were used to compare the baseline patient demo-
graphics, facility type, and clinicopathologic characteristics 
between groups of propensity-matched cases and controls. 
The matched cohorts (i.e., HVF vs. LVF) were compared 
using a log-rank test, and the hazards ratio (HR) was derived 
using univariable Cox regression.37 A two-sided p-value of 
less than 0.05 was used to determine statistical significance. 
All analyses were performed using Stata SE version 13.0 
(College Station, TX).
RESULTS
A total of 10,072 patients were included in our analy-
sis. The range for facility volume was 1–28 CCRT cases each 
year with a median annual volume of 5.3 cases. The ninetieth 
percentile cutoff was identified as 12.3 (rounded to 12) cases 
per year. Therefore, 1207 (12.0%) patients were treated at 
HVF with ≥12 cases per year, and 8866 (88.0%) patients were 
treated at LVF with less than 12 cases per year.
Table 1 presents the demographic and clinical characteris-
tics and treatment patterns of patients who were treated at HVF 
versus LVF. On multivariable logistic regression analysis, HVF 
were more likely to be categorized as an academic center than 
LVF (odds ratio = 4.28; 95% confidence interval [CI]: 3.72–
4.93). Patients in HVF were also more likely to have a higher 
Charlson/Deyo comorbidity score, more advanced nodal stage, 
higher RT doses of 66.1–74.0 Gy compared with 59.4–66.0 Gy, 
and three-dimensional conformal RT or intensity-modulated RT 
compared with nonconformal RT (Table 2). Patients with non-
Black race, who lived in counties with a higher median house-
hold income, or traveled a greater distance for treatment, were 
also more likely to undergo CCRT at HVF.
TABLE 1.  Patient Demographic and Clinicopathologic 
Characteristics by Facility Volume Category
Characteristic
Low-Volume,  
N = 8865
High-Volume, 
N = 1207 P Valuea
Facility type <0.001
  Nonacademic 6753 (92.0) 587 (8.0)
  Academic 2112 (77.3) 620 (22.7)
Radiation dose <0.001
  59.4–66.0 Gy 7930 (88.9) 989 (11.1)
  66.1–74.0 Gy 935 (81.1) 218 (18.9)
Radiation modality <0.001
  Intensity-modulated 202 (81.5) 46 (18.5)
  3D-conformal 1311 (85.8) 217 (14.2)
  Nonconformal 7352 (88.6) 944 (11.4)
Facility location <0.001
  Northeast 1764 (89.5) 208 (10.5)
  South 2497 (80.1) 621 (19.9)
  Midwest 2904 (90.0) 322 (10.0)
  West 1700 (96.8) 56 (3.2)
Sex 0.27
  Male 5304 (88.3) 702 (11.7)
  Female 3561 (87.6) 505 (12.4)
Age in years 0.67
  18–59 2671 (88.4) 349 (11.6)
  60–69 3121 (87.5) 446 (12.5)
  70–79 2523 (88.1) 340 (11.9)
  ≥80 550 (88.4) 72 (11.6)
Race 0.39
  White non-Hispanic 7328 (87.8) 1, 019 (12.2)
  Black 1150 (88.9) 144 (11.1)
  White Hispanic 138 (88.5) 18 (11.5)
  Other 239 (90.6) 26 (9.5)
Primary payer 0.14
  Private Insurance 302 (87.5) 43 (12.5)
No insurance 3153 (88.9) 394 (11.1)
  Medicaid 563 (88.5) 73 (11.5)
  Medicare 4533 (87.6) 641 (12.4)
  Other government/ 
unknown
315 (84.9) 56 (15.1)
Median income quartile 0.48
  <$30,000 1428 (87.9) 196 (12.1)
  $30,000–35,000 1814 (89.1) 222 (10.9)
  $35,000–45,999 2626 (87.6) 373 (12.4)
  ≥$46,000 2621 (87.9) 361 (12.1)
  Unknown 376 (87.0) 56 (13.0)
Urbanization 0.002
  Metro 6546 (88.7) 837 (11.3)
  Urban 1712 (86.7) 262 (13.3)
  Rural 607 (84.9) 108 (15.1)
Year of diagnosis 0.11
  2004 2940 (87.7) 414 (12.3)
  2005 2987 (87.4) 429 (12.6)
  2006 2938 (89.0) 364 (11.0)
(Continued)
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Median survival times were 19.7 months (95% CI: 
18.3–20.9) for patients treated in HVF and 17.3 months 
(95% CI: 16.9–17.8) for patients treated in LVF (p = 0.02; 
Fig. 2A). After controlling for demographic and clinical 
factors in Cox proportional hazards modeling, treatment at 
HVF was independently associated with a decreased hazard 
of death (HR = 0.93; 95% CI: 0.87–0.99; p = 0.03; Table 3). 
Academic affiliation was not associated with overall survival 
(HR = 0.98; 95% CI: 0.93–1.03; p = 0.42).
Propensity score matching yielded 1207 pairs of 
patients who were treated at HVF and LVF. After propensity 
score matching, there were no meaningful differences on any 
observed measure between patients treated at HVF and LVF 
(Supplemental Table 2, Supplemental Digital Content, http://
links.lww.com/JTO/A819). KaplanMeier survival analysis con-
tinued to show improved survival among patients in HVF 
(p = 0.04; Fig. 2B), and Cox proportional hazards modeling of 
the propensity score-matched cohort showed a similar survival 
benefit with treatment at HVF (HR = 0.91; 95% CI: 0.84–
0.99; p = 0.04). Sensitivity analysis showed that when HVF was 
defined as facilities with at least 6, 7, 8, 9, 10, or 11 cases per year, 
volume was not associated with improved survival (Table 4).
DISCUSSION
We found that patients treated with definitive CCRT 
for stage III NSCLC in HVF (≥12 cases per year) achieved 
improved overall survival compared with LVF, independent 
T Stage 0.70
  T1 1079 (87.2) 158 (12.8)
  T2 2933 (87.8) 408 (12.2)
  T3 1660 (88.3) 219 (11.7)
  T4 3193 (88.3) 422 (11.7)
N Stage 0.02
  N0 825 (90.6) 86 (9.4)
  N1 556 (90.1) 61 (9.9)
  N2 5627 (87.6) 796 (12.4)
  N3 1857 (87.6) 264 (12.4)
Charlson–Deyo score 0.35
  0 6321 (88.3) 839 (11.7)
  1 1953 (87.6) 277 (12.4)
  2 591 (86.7) 91 (13.3)
Histology 0.21
  Squamous cell 3281 (88.9) 411 (11.1)
  Large cell 372 (86.9) 56 (13.1)
  Adenocarcinoma 2226 (87.3) 325 (12.7)
  Other NSCLC 2987 (87.8) 415 (12.2)
Travel distance <0.001
  <20 miles 6593 (89.8) 750 (10.2)
  ≥20 miles 1990 (82.6) 418 (17.4)
  Unknown 282 (87.9) 39 (12.1)
aThe χ2 test.
TABLE 2.  Predictors of Treatment at High-Volume Facilities 
on Multivariable Logistic Regression Analysis
Characteristic (Reference)
Odds Ratio (95% 
Confidence Interval) P Value
Facility type (nonacademic)
  Academic 4.28 (3.72–4.93) <0.001
Radiation dose (59.4–66.0 Gy)
  66.1–74.0 Gy 1.52 (1.33–1.75) <0.001
Radiation modality (nonconformal)
  3D-conformal 1.79 (1.25–2.57) 0.001
  Intensity-modulated 1.43 (1.20–1.69) <0.001
Facility location (Northeast)
  South 3.34 (2.76–4.05) <0.001
  Midwest 1.14 (0.94–1.39) 0.18
  West 0.42 (0.31–0.58) <0.001
Sex
  Female 1.10 (0.97–1.26) 0.15
Age in years (18–59)
  60–69 1.12 (0.94–1.34) 0.20
  70–79 1.17 (0.94–1.46) 0.15
  ≥80 1.19 (0.87–1.63) 0.28
Race (White non-Hispanic)
  Black 0.75 (0.61–0.92) 0.007
  White Hispanic 1.03 (0.58–1.80) 0.93
  Other 0.90 (0.58–1.40) 0.63
Primary payer (private insurance)
  No insurance 0.95 (0.66–1.37) 0.78
  Medicaid 0.92 (0.69–1.22) 0.56
  Medicare 1.08 (0.90–1.29) 0.41
  Other government/unknown 1.12 (0.80–1.57) 0.50
Median income quartile (<$30,000)
  $30,000–35,000 1.03 (0.82–1.28) 0.82
  $35,000–45,999 1.42 (1.15–1.74) 0.001
  ≥$46,000 1.46 (1.17–1.83) 0.001
  Unknown 1.45 (0.82–2.57) 0.21
Urbanization (metro)
  Urban 1.20 (0.99–1.45) 0.06
  Rural 1.43 (1.05–1.93) 0.02
Year of diagnosis (2004)
  2005 0.98 (0.84–1.14) 0.77
  2006 0.81 (0.69–0.95) 0.008
T stage (T1)
  T2 0.97 (0.79–1.20) 0.81
  T3 0.96 (0.75–1.22) 0.75
  T4 1.08 (0.86–1.34) 0.51
N stage (N0)
  N1 1.20 (0.82–1.75) 0.34
  N2 1.40 (1.07–1.83) 0.01
  N3 1.41 (1.05–1.89) 0.02
Charlson–Deyo score (0)
  1 1.17 (1.00–1.37) 0.047
  2 1.37 (1.07–1.76) 0.01
TABLE 1. (Continued )
Characteristic
Low-Volume, N 
= 8865
High-Volume, 
N = 1207 P Valuea
(Continued)
Copyright © 2014 by the International Association for the Study of Lung Cancer
941Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 6, June 2015 RT Volume and Survival in Stage III NSCLC
of academic affiliation. This effect was persistent after 
adjusting for covariates using multivariable Cox regression 
and on sensitivity analyses using propensity score match-
ing. To our knowledge, this is the first study showing a 
provider volume–outcome relationship in definitive CCRT 
for NSCLC. Our findings are concordant with results from 
other studies showing that patients who receive cancer treat-
ment at LVF have poorer survival. However, the majority 
of these studies focused on surgical volume, with the few 
Histology (squamous cell)
  Large cell 1.33 (0.97–1.84) 0.08
  Adenocarcinoma 1.18 (1.00–1.39) 0.06
  Other NSCLC 1.08 (0.92–1.25) 0.35
Travel distance (<20 miles)
  ≥20 miles 1.60 (1.36–1.88) <0.001
  Unknown 0.67 (0.35–1.40) 0.31
FIGURE 2.  KaplanMeier estimates of overall survival accord-
ing to facility volume category (A) before propensity score 
matching and (B) after propensity score matching.
TABLE 3.  Cox Proportional Hazards Multivariable Model for 
Predictors of Overall Survival
Characteristic 
(Reference)
Hazard Ratio (95% 
Confidence Interval) P Value
Facility volume (low-volume)
  High-volume 0.93 (0.87–0.99) 0.03
Facility type (nonacademic)
  Academic 0.98 (0.93–1.03) 0.42
Radiation dose (59.4–66.0 Gy)
  66.1–74.0 Gy 0.96 (0.92–1.01) 0.12
Radiation modality (nonconformal)
  3D-conformal 0.88 (0.76–1.01) 0.07
  Intensity-modulated 0.94 (0.88–0.99) 0.03
Facility location (Northeast)
  South 1.03 (0.96–1.10) 0.40
  Midwest 1.01 (0.95–1.07) 0.67
  West 0.93 (0.87–1.01) 0.07
Sex
  Female 0.86 (0.82–0.90) <0.001
Age in years (18–59)
  60–69 1.08 (1.01–1.14) 0.02
  70–79 1.23 (1.15–1.33) <0.001
  ≥80 1.44 (1.32–1.62) <0.001
Race (White non-Hispanic)
  Black 0.90 (0.84–0.97) 0.002
  White Hispanic 0.93 (0.78–1.11) 0.40
  Other 0.86 (0.75–0.98) 0.03
Primary payer (private insurance)
  No insurance 1.10 (0.97–1.25) 0.13
  Medicaid 1.09 (1.00–1.20) 0.07
  Medicare 1.08 (1.02–1.15) 0.009
  Other government/ 
unknown
1.10 (0.97–1.24) 0.12
Median income quartile (<$30,000)
  $30,000–35,000 0.93 (0.87–1.00) 0.06
  $35,000–45,999 0.91 (0.85–0.98) 0.009
  ≥$46,000 0.87 (0.81–0.94) <0.001
  Unknown 0.86 (0.70–1.05) 0.15
Urbanization (metro)
  Urban 1.00 (0.94–1.06) 0.94
  Rural 1.08 (0.96–1.20) 0.20
Year of diagnosis (2004)
  2005 0.94 (0.89–0.99) 0.01
  2006 0.93 (0.88–0.98) <0.001
T Stage (T1)
  T2 1.22 (1.13–1.31) <0.001
  T3 1.34 (1.24–1.46) <0.001
  T4 1.41 (1.31–1.52) <0.001
N Stage (N0)
  N1 1.24 (1.11–1.39) <0.001
  N2 1.20 (1.11–1.31) <0.001
  N3 1.39 (1.27–1.52) <0.001
TABLE 2. (Continued )
Characteristic (Reference)
Odds Ratio (95% 
Confidence Interval) P Value
(Continued)
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assessments of RT volume examining practice for head and 
neck or cervical cancer.13–22
The underlying reasons for our finding of improved 
survival at HVF are unclear. The outcomes observed at HVF 
may be artificially influenced in either direction by refer-
ral patterns and selection bias. We found that patients from 
higher income regions, who had private insurance, and who 
traveled a greater distance to seek care were more likely to be 
treated at HVF. Thus, a possible explanation for the improved 
outcomes in these facilities may be that patients with greater 
access to economic and social resources may preferentially 
seek care at HVF.7,17,38,39 Conversely, such patients could be 
more likely to be treated surgically after presenting to HVF, 
and so the remaining subset of patients treated at HVF who 
were found to be ineligible for surgery and therefore included 
in our analysis could be in a less favorable risk group than 
those at LVF. In addition, patients deemed to be at too high 
of a risk to undergo treatment at a LVF may be referred to 
HVF for more specialized treatment and supportive care. 
Despite these potential explanations, patients treated at HVF 
were found to be no healthier in terms of comorbidities or 
nodal status than those at LVF, and there was no evidence 
on propensity score matching that selection bias contributed 
strongly to our findings. We could not exclude the possibil-
ity that unmeasured variables like more guideline-supported 
contouring, higher rates of protocol compliance,27,28 and the 
greater availability of experienced diagnostic, therapeutic, 
and supportive services29–31 in both radiation oncology and 
medical oncology at HVF could explain our results. Improved 
multidisciplinary collaboration, more tumor site-specific spe-
cialists, and a differential ability to provide chemotherapy 
and radiation therapy at the same center may also be contrib-
uting to our results as well, though it is impossible to test for 
these hypotheses in the NCDB.
Our findings that more advanced RT techniques were 
associated with improved survival are consistent with results 
from previous studies showing a benefit after adoption of 
computed tomography-based simulation for NSCLC.40 It 
should be noted that facility volume was associated with 
improved survival even after controlling for radiation modal-
ity. We also found that doses of 59.4 to 66.0 Gy were associ-
ated with similar risk of death compared with doses of 66.1 
to 74.0 Gy. These findings may appear to be discordant with 
RTOG 0617, which is a phase III study that revealed inferior 
survival for high-dose (74 Gy) compared to standard-dose 
RT39.  However, they are consistent with recent data from a 
similar observational cohort showing no significant differ-
ence in survival among patients treated within a range of 
59.4-74.0 Gy40. This may also reflect a role for an intermedi-
ate dose between 60 and 74 Gy.43
Our study has several other limitations to consider. 
First, there are several important clinical variables that we 
could not measure because NCDB lacked information regard-
ing the patients’ smoking status, performance status, and pul-
monary function, which may also impact overall survival. We 
were also unable to examine survival among patients diag-
nosed after 2006. Although all patients in this study received 
CCRT, we could not identify the types of agents, number of 
agents, and number of cycles of chemotherapy used. It is also 
important to note that the NCDB facilities are likely to have 
treated more patients with thoracic RT than we have included 
in our study. Our analysis only reflects the number of defini-
tive CCRT cases for NSCLC treated annually because we 
excluded patients receiving definitive or palliative RT alone, 
adjuvant or neoadjuvant RT with or without chemotherapy, 
sequential RT and chemotherapy, or any of the above for 
small-cell lung cancer. We intentionally restricted our sample 
in this way to minimize confounding by variations in disease 
risk or management approaches, but as a result, the generaliz-
ability of our findings may be limited. Finally, the magnitude 
of the survival benefit we observed by volume status is rela-
tively small (increased median survival of 2.4 months), and so 
the clinical significance will need to be examined in greater 
depth by future studies.
In conclusion, we found that treatment at HVF perform-
ing ≥12 definitive CCRT cases per year for stage III NSCLC is 
associated with higher overall survival. Future studies should 
focus on identifying the factors responsible for this differen-
tial survival. Nevertheless, our study suggests that for stage 
III NSCLC patients receiving definitive CCRT, centralization 
of care to HVF may be a potential strategy to optimize patient 
outcomes.
TABLE 4.  Sensitivity Analysis Altering the High-Volume 
Facility Definition in the Cox Proportional Hazards 
Multivariable Model
High-Volume Facility 
Cut-off
Hazard Ratio (95% 
Confidence Interval) P Value
6 0.99 (0.95–1.04) 0.82
7 1.00 (0.95–1.05) 0.95
8 (75th percentile) 0.97 (0.93–1.02) 0.29
9 0.96 (0.91–1.02) 0.19
10 (80th percentile) 0.95 (0.90–1.01) 0.09
11 0.95 (0.89–1.01) 0.09
12 (90th percentile) 0.93 (0.87–0.99) 0.03
Volume as continuous 
variable
1.00 (0.99–1.00) 0.09
Charlson–Deyo score (0)
  1 1.11 (1.06–1.17) <0.001
  2 1.22 (1.13–1.33) <0.001
Histology (squamous cell)
  Large cell 0.92 (0.82–1.02) 0.12
  Adenocarcinoma 0.96 (0.90–1.01) 0.12
  Other NSCLC 1.00 (0.95–1.05) 0.85
Travel distance (<20 miles)
  ≥20 miles 0.93 (0.88–0.99) 0.02
  Unknown 1.00 (0.78–1.28) 1.00
TABLE 3. (Continued )
Characteristic 
(Reference)
Hazard Ratio (95% 
Confidence Interval) P Value
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